SASKATOON, Saskatchewan, Aug. 15, 2025 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation“) (TSXV:PCRX) a growing national platform for pharmacist-led community pharmacy ownership, today reported its financial results for the three and six months ended June 30, 2025.
The second quarter reflected continued operational momentum, expanding pharmacy-level contribution, and disciplined progress on the Corporation’s national acquisition strategy. Following quarter-end, PharmaCorp completed the acquisition of a fourth pharmacy in Western Canada, building further scale and reinforcing the platform’s coast-to-coast ambitions.
Q2 2025 Financial Highlights
- Revenues generated from three operating pharmacies, with continued growth in both prescription volumes and front-of-store sales
- Operating infrastructure was successfully deployed to support national scalability, including systems integration, pharmacy onboarding, and co-ownership execution
- Net loss for the quarter reflects continued investment in corporate infrastructure and the catch-up of executive compensation deferred from 2024
- Solid pharmacy-level contribution margins and a consistent weighted average EBITDA multiples across acquisitions support PharmaCorp’s long-term accretive growth model
- A strong balance sheet positions the Corporation to fund additional acquisitions already under letter of intent
- Same-store sales, a supplementary financial measure, increased 11.3% year-over-year compared to Q2 2024, reflecting continued organic growth across our pharmacy network
- Prescription volumes continue to grow, with total script count rising 3.5% year-over-year compared to Q2 2024, demonstrating sustained patient engagement and activity across the network
Management Commentary
“We are pleased with the momentum we’re seeing across our early acquisitions and the continued appetite from independent pharmacy owners exploring succession,” said Alan Simpson, Executive Chairman of PharmaCorp. “This quarter reflects continued progress in scaling our platform through disciplined execution. We continue to maintain a consistent, disciplined weighted average EBITDA multiple across our acquisitions, which supports our goal of delivering accretive growth. As we expand our national footprint, we remain focused on sourcing high-quality pharmacies that align with our long-term acquisition strategy and contribute meaningfully to accretion.”
Operational Update
During the quarter, the Corporation made key investments in systems, personnel, and integration processes necessary to support scalable national growth. The reported net loss includes compensation charges related to deferred 2024 executive remuneration, which were brought current in Q2 as part of aligning leadership incentives with long-term shareholder value.
Subsequent Events
On July 31, 2025, the Corporation closed the acquisition of its fourth pharmacy, located in Western Canada, further expanding its national footprint and operating base under the PharmaCorp co-ownership platform.
On August 13, 2025, the Corporation entered into a credit agreement with Canadian Imperial Bank of Commerce (“CIBC“) providing the Corporation with up to $20,500,000 of committed credit facilities (the “Credit Facilities“), plus a $10,000,000 accordion feature and a $1,000,000 Visa credit facility. The Credit Facilities will support PharmaCorp’s acquisition strategy and the expansion of its acquisition and operating platforms. In conjunction with the above Credit Facilities, CIBC is also supporting PharmaCorp’s Pharmacist Co-Ownership Program through a separate $5,000,000 credit facility which makes loans available to pharmacists wishing …